Mirum Pharmaceuticals

Menlo Park, United States Founded: 2018 • Age: 8 yrs Listed
Small molecule therapeutics are developed for rare diseases treatment.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a publicly listed company based in Menlo Park (United States) founded in 2018. Small molecule therapeutics are developed for rare diseases treatment. Mirum Pharmaceuticals has raised $120 million across 3 funding rounds from investors including Frazier Healthcare Partners, Oberland Capital and NEA. The company has 322 employees. Mirum Pharmaceuticals has completed 2 acquisitions, including Bluejay Therapeutics and Satiogen. Its chief executive, as recorded, is Christopher Peetz. Its website mirumpharma.com draws about 19 thousand monthly visits. Mirum Pharmaceuticals offers products and services including LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its competitors include Alnylam, Ultragenyx and NGM Biopharmaceuticals; 3 of its 3 listed competitors have raised funding.

Company details

Mirum Pharmaceuticals was founded in 2018 and is headquartered in Menlo Park, United States. Small molecule therapeutics are developed by the company to address rare diseases, focusing on cholestatic conditions. The lead candidate, Maralixibat, is targeted at Alagille syndrome and progressive familial intrahepatic cholestasis by inhibiting bile acid transport. Volixibat is being advanced for adult cholestasis. Operations center on pharmaceutical research and development in the rare disease sector.

  • Headquarters Menlo Park, United States
  • Employees 322
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website mirumpharma.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Mirum Pharmaceuticals, Inc.
Key Metrics
  • Annual Revenue
    $521.31 M (USD)
    54.74
    as on Dec 31, 2025
  • Net Profit
    -$23.36 M (USD)
    73.43
    as on Dec 31, 2025
  • EBITDA
    $2.11 M (USD)
    as on Dec 31, 2025
  • Total Equity Funding
    $120M (USD)

    in 3 rounds

  • Latest Funding Round
    $68.48M (USD), Post-IPO

    Jan 2026

  • Investors
  • Employee Count
    322
  • Investments & Acquisitions

Products & Services of Mirum Pharmaceuticals

Mirum Pharmaceuticals offers a comprehensive portfolio of products and services, including LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program.

LIVMARLI
Medicine

Treatment for cholestasis in rare diseases patients.

Cholbam
Medicine

Therapy for inborn errors of bile acid metabolism.

CTEXLI
Medicine

Support for genetic neurology conditions in patients.

Diagnostic Testing Program
Service

Program for testing rare diseases through healthcare partners.

Funding Insights of Mirum Pharmaceuticals

Mirum Pharmaceuticals has successfully raised a total of $120M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $68.48 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $120M
  • Total Rounds 3
  • Last Round Post-IPO β€” $68.48M
  • First Round $120M

    (Nov 2018)

  • Investors Count 8

All 3 funding rounds of Mirum Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2026$68.48MPost-IPO––
–
Dec 2020$10MPost-IPO––
Nov 2018$120MSeries A–New Enterprise Associates
Valuation history

8 investors in total: 8 institutional.

Investors in Mirum Pharmaceuticals

Mirum Pharmaceuticals has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Frazier Healthcare Partners, Oberland Capital and NEA.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
2013oberlandcapital.comNew York, United States
Venture capital investments are offered to startups by NEA.
nea.comMenlo Park, United States
Healthcare ecosystem is supported through investment and innovation by Deerfield.
deerfield.comNew York, United States
Healthcare sector private equity investments are managed by the firm.
1991frazierhealthcare.comSeattle, United States
Private equity and venture capital fund focused on the healthcare sector
novoholdings.dkHellerup, Denmark
VC firm focusing on life science sector
pappas-capital.comDurham, United States
Early-stage and late-stage biotech and finance companies are funded.
rockspringscapital.comBaltimore, United States
rivervest.com
Premium access

Investor details for Mirum Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Mirum Pharmaceuticals

164 people are tracked at Mirum Pharmaceuticals (100 in leadership, 9 in board & advisors, 55 in team); the tracked headcount is 322.

NameRoleGroup
Christopher Peetz
CEOLeadership
Chris Peetz
President & CEOLeadership
Lara Longpre
Chief Development OfficerLeadership
Andrew McKibben
Vice PresidentLeadership
Jolan Terner-Rosenthal
Executive Director, PublicationsLeadership
Peter Radovich
COOLeadership
Youngson Kim
Director Commercial Product QCQALeadership
Nataliia Menon
Associate Director International Distributor ManagementLeadership
Kathy Chu
Director, Global ForecastingLeadership
Luis Polo-Carbayo
Associate Director, Post Marketing Studies ManagementLeadership
Jennifer Whaley
Regional Director Of Msls / West RegionLeadership
Emmanuelle Nuris-Souquet
General Manager France And BeneluxLeadership
Eva Ruth
Senior Director Of Gcp/gvp/glp QALeadership
Jeffrey Murtha
Executive Director, Head Of US Metabolic SalesLeadership
Jody Legg
Sr. Director, Head US Payer FunctionLeadership
Philipp Anstaett-Pfeifer
Director Commercial OperationsLeadership
Renee Shiota
Senior Director, Trade, Distribution And Patient ServicesLeadership
Anita Dreyer
Director Clinical DevelopmentLeadership
Jj Roth
Sr National Account Director, Managed MarketsLeadership
Marc Clausse
Vp, International Commercial OperationsLeadership

144 more people are available in the full profile.

Premium access

Complete people profiles for Mirum Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Mirum Pharmaceuticals

Mirum Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol MIRM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Jul 2019
  • Listed onNASDAQ: MIRM
  • Listed entityMirum Pharmaceuticals, Inc.
  • Exchange sectorHealth technology
  • ISINUS6047491013
  • Share price$79.62 (-7.48% on the day) · 2026-10-13
  • Market capitalisation$5.17B
  • EPS (diluted, trailing year)$-14.55
  • Volume (last session)762,633

Financials of Mirum Pharmaceuticals

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$521.3M-$23.4M$2.1M
2024$336.9M-$87.9M-$64.0M
2023$186.4M-$163.4M-$98.3M
2022$77.1M-$135.7M-$127.5M
2021$19.1M-$84.0M-$172.4M
Premium access

Detailed financial statements for Mirum Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Mirum Pharmaceuticals

Mirum Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bluejay Therapeutics and Satiogen.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Therapeutics for infectious diseases treatment are developed.
bluejaytx.comSan Francisco, United States2019Dec 2025$620M
Specialty pharma company focused on developing treatment for diabetes
satiogen.comSan Diego, United States2007May 2022β€’β€’β€’β€’
Premium access

Complete acquisition details for Mirum Pharmaceuticals

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Mirum Pharmaceuticals

6 dated milestones of Mirum Pharmaceuticals across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Mirum Pharmaceuticals is founded.
  2. Funding First funding round of $120.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Satiogen.
  5. Acquisition Acquires Bluejay Therapeutics.
  6. Funding Latest funding round, Post-IPO, of $68.5M.

Competitors of Mirum Pharmaceuticals

Mirum Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and NGM Biopharmaceuticals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
alnylam.com2002Cambridge, United States$17M2,100
RNA interference-based therapeutics are developed for multiple disorders.
ultragenyx.com2010Novato, United States$135.1M837
Therapeutics for rare and ultra-rare metabolic diseases are developed.
ngmbio.com2007San Francisco, United States$358.87M225
Biologics are developed for cardio-metabolic and liver diseases.
Premium access

Detailed competitors of Mirum Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Mirum Pharmaceuticals

The website of Mirum Pharmaceuticals (mirumpharma.com) receives about 18.5K visits a month and ranks #1,354,049 among all websites worldwide, #1,754 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    18.5K
  • Unique visitors
    8.4K

    per month

  • Global rank
    #1,354,049

    among all websites

  • Category rank
    #1,754

    Health · Biotechnology and Pharmaceuticals

Top companies in Metabolic Diseases

3 companies that operate in the same segment as Mirum Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
2009Wellesley, Massachusetts, United StatesUSD 174.04 MUSD 32.11 M137
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
2010Boston, Massachusetts, United StatesUSD 84 MUSD 189.76 M283
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Mirum Pharmaceuticals

Premium access

Complete news archive for Mirum Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mirum Pharmaceuticals

Mirum Pharmaceuticals was founded in 2018.

Mirum Pharmaceuticals is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.

Christopher Peetz is the CEO of Mirum Pharmaceuticals, as recorded in our data.

Mirum Pharmaceuticals is a funded company, having raised a total of $120M across 3 funding rounds to date. The company's 1st funding round was a Series A of $120M, raised on Nov 2018.

Mirum Pharmaceuticals has 322 employees.

Annual revenue of Mirum Pharmaceuticals is $521.31M as on Dec 31, 2025.

Mirum Pharmaceuticals was founded in 2018 and is headquartered in Menlo Park, United States. Small molecule therapeutics are developed by the company to address rare diseases, focusing on cholestatic conditions. The lead candidate, Maralixibat, is targeted at Alagille syndrome and progressive familial intrahepatic cholestasis by inhibiting bile acid transport. Volixibat is being advanced for adult cholestasis. Operations center on pharmaceutical research and development in the rare disease sector.

Mirum Pharmaceuticals's top competitors include Alnylam, NGM Biopharmaceuticals and Ultragenyx.

Mirum Pharmaceuticals offers LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program.

Yes, Mirum Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol MIRM.

Mirum Pharmaceuticals has made 2 acquisitions, including Bluejay Therapeutics, and Satiogen.

Mirum Pharmaceuticals has 8 investors. Key investors include Frazier Healthcare Partners, Oberland Capital, NEA, Deerfield, and Novo Holdings.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available